Signals we assess
Clinical indicators we measure at intake
Klarity’s intake consult benchmarks neurodegenerative disorders biomarkers, mood-tracking patterns, cognitive performance, and nervous system resilience. The result is a precision roadmap that prioritizes regulation before any infusion or neuromodulation begins.
- Early cognitive decline impacting executive function including Alzheimer's disease.
- Patients navigating early Parkinson's disease, Multiple Sclerosis, or post-COVID neurological changes.
- Symptomatic improvement for Traumatic Brain Injuries (TBI), Strokes, and presumed Chronic Traumatic Encephalopathy (CTE).
- Caregivers seeking proactive brain health strategies
Personalized protocols
How our team delivers regenerative neurodegenerative disorders treatment
Your integrated care team pairs our proprietary NAD+ and ketamine-enhanced therapy along with other IV components, neuromodulation, nutrient optimization, and hospitality-level recovery spaces. The plan flexes around real-time data so the protocol stays aligned with your goals.
- Low-dose ketamine protocols paired with cognitive rehabilitation.
- Our NAD+ and nicotinamide riboside infusions for cellular support.
- Psychotherapy and lifestyle design focused on neuroplasticity and caregiver education.
Integration & outcomes
Sustained gains beyond the infusion chair
Klarity tracks every phase of your neurodegenerative disorders progress with validated assessments, biometric feedback, and a curated integration playbook. Expect concierge check-ins, habit scaffolding, and cross-talk with your existing providers to keep breakthroughs anchored.